Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001308212 | SCV001497651 | uncertain significance | Cranioectodermal dysplasia 1 | 2022-09-19 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 454 of the IFT122 protein (p.Ile454Leu). This variant is present in population databases (rs149915993, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with IFT122-related conditions. ClinVar contains an entry for this variant (Variation ID: 1010568). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt IFT122 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002543226 | SCV003691222 | uncertain significance | Inborn genetic diseases | 2021-09-27 | criteria provided, single submitter | clinical testing | The c.1360A>C (p.I454L) alteration is located in exon 13 (coding exon 13) of the IFT122 gene. This alteration results from a A to C substitution at nucleotide position 1360, causing the isoleucine (I) at amino acid position 454 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV001308212 | SCV005659552 | uncertain significance | Cranioectodermal dysplasia 1 | 2024-06-18 | criteria provided, single submitter | clinical testing |